Traynor Capital Management Inc. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 7.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 60,928 shares of the company’s stock after buying an additional 4,432 shares during the period. Novo Nordisk A/S comprises about 1.2% of Traynor Capital Management Inc.’s holdings, making the stock its 15th largest position. Traynor Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $2,530,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NVO. Guggenheim Capital LLC boosted its position in shares of Novo Nordisk A/S by 4.3% in the fourth quarter. Guggenheim Capital LLC now owns 35,235 shares of the company’s stock valued at $1,264,000 after buying an additional 1,442 shares during the last quarter. Creative Planning boosted its position in shares of Novo Nordisk A/S by 63.3% in the first quarter. Creative Planning now owns 40,622 shares of the company’s stock valued at $1,393,000 after buying an additional 15,746 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Novo Nordisk A/S by 64.7% in the first quarter. Bank of Montreal Can now owns 65,178 shares of the company’s stock valued at $2,234,000 after buying an additional 25,611 shares during the last quarter. Gradient Investments LLC boosted its position in shares of Novo Nordisk A/S by 317.7% in the first quarter. Gradient Investments LLC now owns 7,590 shares of the company’s stock valued at $260,000 after buying an additional 5,773 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its position in shares of Novo Nordisk A/S by 5.8% in the first quarter. Capstone Asset Management Co. now owns 76,085 shares of the company’s stock valued at $2,608,000 after buying an additional 4,170 shares during the last quarter. 6.40% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S (NYSE:NVO) traded up 3.65% on Friday, reaching $45.76. 421,467 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $42.69 and a 200-day moving average price of $38.73. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $47.98. The company has a market capitalization of $113.56 billion, a PE ratio of 18.72 and a beta of 0.63.

The firm also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st will be issued a $0.336 dividend. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date is Friday, August 18th. This represents a yield of 1.07%. Novo Nordisk A/S’s payout ratio is 35.84%.

WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/traynor-capital-management-inc-purchases-4432-shares-of-novo-nordisk-as-nvo.html.

NVO has been the topic of several recent research reports. Zacks Investment Research cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, April 19th. TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Finally, BidaskClub raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Five research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $53.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.